Kewaunee Scientific Soars on Nu Aire Boost, Net Sales Up 47%

TL;DR

**KEQU's Nu Aire acquisition is paying off big, driving massive sales and profit growth – definitely one to watch!**

AI Summary

KEWAUNEE SCIENTIFIC CORP /DE/ reported a strong financial performance for the three months ended July 31, 2025, with net sales increasing by 46.9% to $71.104 million from $48.393 million in the prior year. Net earnings attributable to Kewaunee Scientific Corporation stockholders rose by 41.0% to $3.093 million, up from $2.193 million in the same period last year. Basic net earnings per share increased to $1.08 from $0.77. The acquisition of Nu Aire, Inc. on November 1, 2024, significantly contributed to this growth, adding $19.7 million in revenue and $696,000 in net earnings for the quarter. Operating profit more than doubled, reaching $4.810 million compared to $2.575 million in the previous year. However, interest expense also increased substantially to $1.058 million from $472,000, largely due to financing for the Nu Aire acquisition. The company's cash and cash equivalents increased to $19.489 million from $14.942 million at April 30, 2025, driven by $5.791 million in net cash provided by operating activities.

Why It Matters

This strong performance, particularly the significant revenue and earnings growth, signals robust demand in the laboratory furnishings and technical products market, which could attract more investor interest in KEQU and its competitors. The successful integration and contribution of Nu Aire demonstrate KEQU's ability to execute strategic acquisitions, potentially strengthening its market position against rivals like Thermo Fisher Scientific or Avantor in specialized lab equipment. For employees, this growth could mean job security and expansion opportunities, while customers benefit from an expanded product portfolio and enhanced capabilities. The increased interest expense, however, highlights the financial leverage taken on for the Nu Aire acquisition, a factor investors should monitor closely.

Risk Assessment

Risk Level: medium — While net earnings increased by 41.0% to $3.093 million, interest expense more than doubled to $1.058 million from $472,000, indicating increased debt burden from the Nu Aire acquisition. Additionally, foreign currency translation adjustments resulted in an 'other comprehensive loss' of $410,000, up from $116,000, exposing the company to currency fluctuation risks.

Analyst Insight

Investors should consider KEQU's strong revenue and earnings growth driven by the Nu Aire acquisition as a positive indicator. However, they should also scrutinize the increased interest expense and foreign currency risks, and monitor future debt repayment schedules and currency hedging strategies.

Financial Highlights

revenue

$71.104M

operating Margin

6.77%

net Income

$3.093M

eps

$1.08

gross Margin

29.43%

cash Position

$19.489M

revenue Growth

+46.9%

Revenue Breakdown

Key Numbers

• $71.104M — Net sales (Increased by 46.9% from $48.393M year-over-year)
• $3.093M — Net earnings attributable to Kewaunee Scientific Corporation (Increased by 41.0% from $2.193M year-over-year)
• $1.08 — Basic net earnings per share (Increased from $0.77 year-over-year)
• $19.7M — Nu Aire revenue contribution (Revenue from Nu Aire for the three months ended July 31, 2025)
• $696K — Nu Aire net earnings contribution (Net earnings from Nu Aire for the three months ended July 31, 2025)
• $4.810M — Operating profit (Increased from $2.575M year-over-year)
• $1.058M — Interest expense (Increased from $472K year-over-year due to acquisition financing)
• $5.791M — Net cash provided by operating activities (Significant improvement from net cash used of $794K year-over-year)
• $53.0M — Aggregate acquisition consideration for Nu Aire (Total purchase price for Nu Aire acquisition)
• $410K — Foreign currency translation adjustments (Other comprehensive loss, increased from $116K year-over-year)

Key Players & Entities

• KEWAUNEE SCIENTIFIC CORP /DE/ (company) — registrant
• Nu Aire, Inc. (company) — acquired company
• PNC Bank, National Association (company) — lender for acquisition financing
• SEC (regulator) — Securities and Exchange Commission
• NASDAQ Global Market (market) — exchange where KEQU common stock is registered
• Thermo Fisher Scientific (company) — potential competitor
• Avantor (company) — potential competitor
• Delaware (location) — state of incorporation
• Statesville, North Carolina (location) — principal executive offices

FAQ

Risk Factors

• Integration of Acquired Businesses [high — operational]: The company's growth strategy relies on successful integration of acquired businesses, such as Nu Aire, Inc. Failure to effectively integrate operations, systems, and personnel could disrupt business, impact profitability, and strain management resources. The acquisition of Nu Aire added $19.7 million in revenue and $696,000 in net earnings, indicating its significant contribution, but also the potential impact of integration challenges.
• Increased Indebtedness [medium — financial]: The acquisition of Nu Aire was financed, leading to a substantial increase in interest expense from $472,000 to $1,058,000 for the three months ended July 31, 2025. This increased leverage could make the company more vulnerable to economic downturns and limit its financial flexibility for future investments or operations.
• Competition in Laboratory and Technical Furniture Market [medium — market]: The company operates in a competitive market for laboratory and technical furniture. While the acquisition of Nu Aire has expanded its market presence, intense competition could pressure pricing, market share, and profitability. Specific details on market share or competitive positioning are not provided in this filing.
• Compliance with Environmental and Safety Regulations [low — regulatory]: As a manufacturer of laboratory furniture and equipment, Kewaunee Scientific is subject to various environmental, health, and safety regulations. Non-compliance could result in fines, operational disruptions, and reputational damage. The nature of laboratory environments often necessitates adherence to strict safety standards.

Industry Context

Kewaunee Scientific operates in the laboratory and technical furniture and equipment manufacturing industry. This sector is characterized by demand driven by research and development spending, educational institutions, and healthcare facilities. The industry is competitive, with players differentiating on product quality, customization, safety features, and service. Recent trends include a focus on modular and adaptable laboratory designs to accommodate evolving research needs and increased demand for specialized containment solutions.

Regulatory Implications

As a manufacturer, Kewaunee Scientific is subject to standard manufacturing regulations concerning product safety, environmental impact, and labor practices. Compliance with these regulations is essential to avoid penalties and maintain operational continuity. The nature of laboratory equipment may also involve adherence to specific industry standards for safety and performance, particularly for products used in hazardous environments.

What Investors Should Do

1. Monitor Nu Aire integration progress
2. Analyze debt levels and interest coverage
3. Evaluate organic growth drivers
4. Assess gross and operating margin trends

Key Dates

• 2025-07-31: End of Second Quarter of Fiscal Year 2026 — Reporting period for the strong financial results, including significant revenue and net earnings growth, largely attributed to the Nu Aire acquisition.
• 2024-11-01: Acquisition of Nu Aire, Inc. — This strategic acquisition significantly boosted revenue and net earnings for the reported quarter, demonstrating the company's growth-by-acquisition strategy.
• 2025-04-30: End of First Quarter of Fiscal Year 2026 — Previous reporting period, providing a baseline for year-over-year comparisons of financial performance and cash position.

Glossary

Non-controlling interest

The portion of equity ownership in a subsidiary that is not attributable to the parent company. It represents the claims of outside owners on the net assets and net income of a consolidated subsidiary. (The financial statements show net earnings attributable to Kewaunee Scientific Corporation after deducting net earnings attributable to the non-controlling interest, indicating that Kewaunee Scientific does not own 100% of all consolidated entities.)

Other comprehensive loss

Unrealized gains or losses that bypass the income statement but affect equity. For Kewaunee Scientific, this includes foreign currency translation adjustments. (The company reported a significant other comprehensive loss of $410,000 for the quarter, primarily due to foreign currency translation adjustments, impacting total stockholders' equity.)

Weighted average number of common shares outstanding

The average number of a company's outstanding shares over a specific period, used to calculate earnings per share (EPS). It accounts for changes in the number of shares during the period. (This metric is crucial for calculating both basic and diluted EPS, which were $1.08 and $1.04 respectively for the quarter, showing the impact of share count on per-share profitability.)

Operating profit

Profit generated from a company's normal business operations, calculated as revenue minus cost of goods sold and operating expenses. It excludes interest and taxes. (Operating profit more than doubled to $4.810 million from $2.575 million, highlighting improved operational efficiency and the positive impact of the Nu Aire acquisition on core business performance.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Kewaunee Scientific Corporation has demonstrated robust growth, with net sales surging by 46.9% to $71.104 million, primarily fueled by the acquisition of Nu Aire, Inc. Net earnings attributable to stockholders also saw a substantial increase of 41.0% to $3.093 million, with basic EPS rising to $1.08 from $0.77. Operating profit more than doubled, indicating improved operational performance. However, interest expense has significantly increased due to acquisition financing, rising from $472,000 to $1,058,000. The company also reported a larger foreign currency translation adjustment loss of $410,000 compared to $116,000 in the prior year.

Key Financial Figures

• $2.50 — ange on which registered Common Stock, $2.50 par value KEQU NASDAQ Global Market _

Filing Documents

• kequ-20250731.htm (10-Q) — 750KB
• certification311.htm (EX-31.1) — 4KB
• certification312.htm (EX-31.2) — 4KB
• exhibit321.htm (EX-32.1) — 2KB
• exhibit322.htm (EX-32.2) — 2KB
• certification311001.jpg (GRAPHIC) — 189KB
• certification312001.jpg (GRAPHIC) — 191KB
• exhibit321001.jpg (GRAPHIC) — 86KB
• exhibit322001.jpg (GRAPHIC) — 88KB
• 0000055529-25-000040.txt ( ) — 6697KB
• kequ-20250731.xsd (EX-101.SCH) — 48KB
• kequ-20250731_cal.xml (EX-101.CAL) — 104KB
• kequ-20250731_def.xml (EX-101.DEF) — 188KB
• kequ-20250731_lab.xml (EX-101.LAB) — 608KB
• kequ-20250731_pre.xml (EX-101.PRE) — 416KB
• kequ-20250731_htm.xml (XML) — 781KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements Condensed Consolidated Statements of Operations (unaudited) – Three Months Ended July 31, 2025 and 2024 1 Condensed Consolidated State ments of Comprehensive Earnings (unaudited) – Three Months Ended July 31, 2025 and 2024 2 Condensed Consolidated S tatements of Stockholders' Equity (unaudited) – Three Months Ended July 31, 2025 and 2024 3 Condensed Consol idated Balance Sheets – July 31, 2025 (unaudited) and April 30, 202 5 4 Condensed Consolid ated Statements of Cash Flows (unaudited) – Three Months Ended July 31, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements (unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 21

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1A.

Risk Factors

Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 5. Other Information 22 Item 6. Exhibits 23 SIGNATURE 24 i PART 1. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements Kewaunee Scientific Corporation Condensed Consolidated Statements of Operations (Unaudited) ($ and shares in thousands, except per share amounts) Three Months Ended July 31, 2025 2024 Net sales $ 71,104 $ 48,393 Cost of products sold 50,174 35,905 Gross profit 20,930 12,488 Operating expenses 16,120 9,913 Operating profit 4,810 2,575 Other income, net 168 327 Interest expense ( 1,058 ) ( 472 ) Profit before income taxes 3,920 2,430 Income tax expense 761 192 Net earnings 3,159 2,238 Less: Net earnings attributable to the non-controlling interest 66 45 Net earnings attributable to Kewaunee Scientific Corporation $ 3,093 $ 2,193 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.08 $ 0.77 Diluted $ 1.04 $ 0.74 Weighted average number of common shares outstanding Basic 2,851 2,849 Diluted 2,963 2,967 See accompanying notes to Condensed Consolidated Financial Statements. 1 Kewaunee Scientific Corporation Condensed Consolidated Statements of Comprehensive Earnings (Unaudited) ($ in thousands) Three Months Ended July 31, 2025 2024 Net earnings $ 3,159 $ 2,238 Other comprehensive loss, net of tax: Foreign currency translation adjustments ( 410 ) ( 116 ) Other comprehensive loss ( 410 ) ( 116 ) Comprehensive earnings, net of tax 2,749 2,122 Less: Comprehensive income attributable to the non-controlling interest 66 45 Comprehensive earnings attributable to Kewaunee Scientific Corporation $ 2,683 $ 2,077 See accompanying notes to Condensed Consolidated Financial Statements. 2 Kewaunee Scientific Corporation Condensed Consolidated Statements of Stockholders' Equity (Unaudited) ($ in thousands, except per share amounts) Common Stock Additional Paid-in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Loss Total Kewaunee Scientific Corporation Stockholders' Equity Balance at April 30, 2025 $ 7,353 $

View Full Filing

View this 10-Q filing on SEC EDGAR